Original article: is the protective association between hyperemesis gravidarum and birth defects biased by pregnancy termination?


Journal

Annals of epidemiology
ISSN: 1873-2585
Titre abrégé: Ann Epidemiol
Pays: United States
ID NLM: 9100013

Informations de publication

Date de publication:
07 2021
Historique:
received: 05 11 2020
revised: 17 03 2021
accepted: 17 03 2021
pubmed: 3 4 2021
medline: 29 6 2021
entrez: 2 4 2021
Statut: ppublish

Résumé

We assessed whether the protective association between hyperemesis gravidarum and birth defects could be due to selection bias from exclusion of pregnancy terminations. We designed a cohort study of 2,115,581 live births in Canada, 1990-2016. The main exposure measure was hyperemesis gravidarum. The main outcome measure included any birth defect at delivery. We estimated risk ratios (RR) and 95% confidence intervals (CI) for the association of hyperemesis gravidarum with birth defects in log-binomial regression models, and assessed the extent of selection bias through correction factors. Hyperemesis gravidarum was associated with 0.88 times the risk of birth defects in models not corrected for bias (95% CI 0.82-0.94). Correction for selection bias suggested that if screening for birth defects was associated with 1.33 times the chance of detecting birth defects and having a pregnancy termination, there would be no association with hyperemesis gravidarum. If ultrasound was associated with 2.00 times the chance of detecting birth defects and 1.50 times the risk of pregnancy termination, hyperemesis gravidarum would be associated with 1.27 times the risk of birth defects (95% CI 1.18-1.35). The protective association between hyperemesis gravidarum and birth defects in previous studies may be due to selection bias.

Identifiants

pubmed: 33798708
pii: S1047-2797(21)00051-X
doi: 10.1016/j.annepidem.2021.03.007
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10-15

Subventions

Organisme : CIHR
ID : PJT-156062
Pays : Canada

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interests The authors declare no potential conflicts of interest.

Auteurs

Thomas Boissière-O'Neill (T)

Department of Pharmacy, University of Aix-Marseille, Marseille, France; Institut national de santé publique du Québec, Montreal, QC, Canada.

Mireille E Schnitzer (ME)

Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada.

Antoine Lewin (A)

Department of Obstetrics and Gynecology, University of Sherbrooke, Sherbrooke, QC, Canada; Medical Affairs and Innovation, Héma-Québec, Montreal, QC, Canada.

Marianne Bilodeau-Bertrand (M)

Institut national de santé publique du Québec, Montreal, QC, Canada.

Aimina Ayoub (A)

Institut national de santé publique du Québec, Montreal, QC, Canada; University of Montreal Hospital Research Centre, Montreal, QC, Canada.

Nathalie Auger (N)

Institut national de santé publique du Québec, Montreal, QC, Canada; University of Montreal Hospital Research Centre, Montreal, QC, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, QC, Canada. Electronic address: nathalie.auger@inspq.qc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH